Aprea Therapeutics Inc (APRE)

Dec 19, 2024

HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World

Dec 19, 2024

Dec 13, 2024

Aprea Therapeutics, Inc. Announces Twice Daily Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potential Optimize Clinical Outcomes and Strengthen Clinical Path Forward - Marketscreener.com

Dec 13, 2024

Dec 13, 2024

Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo

Dec 13, 2024

Dec 11, 2024

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward - The Manila Times

Dec 11, 2024

Dec 11, 2024

Aprea Therapeutics Advances Novel Cancer Drug Trial with Breakthrough Dosing Strategy - StockTitan

Dec 11, 2024

Nov 22, 2024

Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN

Nov 22, 2024

Nov 21, 2024

HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World

Nov 21, 2024

Nov 20, 2024

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN

Nov 20, 2024

Nov 20, 2024

Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024

Nov 11, 2024

Aprea Therapeutics (NASDAQ: APRE) Announces Financial Results and Corporate Updates - Defense World

Nov 11, 2024

Nov 10, 2024

Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 10, 2024

Nov 10, 2024

Health Catalyst signs definitive agreement to acquire Intraprise Health - MSN

Nov 10, 2024

Nov 07, 2024

Aprea Therapeutics Inc (APRE) Quarterly 10-Q Report - Quartz

Nov 07, 2024

Nov 07, 2024

Aprea Therapeutics Inc (APRE) Q3 2024 Earnings: Revenue Hits $0. - GuruFocus.com

Nov 07, 2024

Nov 07, 2024

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024

Oct 31, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo

Oct 31, 2024

Oct 29, 2024

Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN

Oct 29, 2024

Oct 28, 2024

DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR

Oct 28, 2024

Oct 27, 2024

Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews

Oct 27, 2024

Oct 26, 2024

Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World

Oct 26, 2024

Oct 26, 2024

Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa

Oct 26, 2024

Oct 25, 2024

Aprea therapeutics director sells shares worth $29,583 - Investing.com India

Oct 25, 2024

Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com

Oct 24, 2024

Oct 24, 2024

Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance

Oct 24, 2024

Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK

Oct 24, 2024

Oct 23, 2024

Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance

Oct 23, 2024

Oct 23, 2024

Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha

Oct 23, 2024

Oct 23, 2024

Aprea reports safe trial results for new cancer drug - Investing.com

Oct 23, 2024

Oct 23, 2024

Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK

Oct 23, 2024

Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times

Oct 23, 2024

Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News

Oct 23, 2024

Oct 20, 2024

Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St

Oct 20, 2024

Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa

Oct 17, 2024

Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India

Oct 17, 2024

Oct 17, 2024

Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa

Oct 17, 2024

Oct 17, 2024

Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com

Oct 17, 2024

Oct 17, 2024

Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India

Oct 17, 2024

Oct 16, 2024

Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com

Oct 16, 2024

Oct 16, 2024

Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa

Oct 16, 2024

Oct 16, 2024

Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024

Oct 16, 2024

Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates - MSN

Oct 16, 2024

Oct 16, 2024

Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia

Oct 16, 2024

Oct 16, 2024

Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India

Oct 16, 2024

Oct 15, 2024

Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo

Oct 15, 2024